Comparative Pharmacology
Head-to-head clinical analysis: MEPERIDINE HYDROCHLORIDE versus METHADOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEPERIDINE HYDROCHLORIDE versus METHADOSE.
MEPERIDINE HYDROCHLORIDE vs METHADOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meperidine is a synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system, mimicking endogenous endorphins to produce analgesia. It also has weak serotonergic activity.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
50-150 mg orally or intramuscularly every 3-4 hours as needed for pain. Maximum single dose: 150 mg. Maximum daily dose: 600 mg.
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
None Documented
None Documented
3-4 hours in normal renal function; prolonged to >12 hours in hepatic impairment (cirrhosis) or renal failure (normeperidine accumulates)
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Renal: 70-80% as metabolites (normeperidine ~20%, meperidinic acid ~50%) and <5% unchanged; biliary/fecal: <10%
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Category D/X
Category C
Opioid Agonist
Opioid Agonist